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ABSTRACT
Innate lymphoid cells (ILCs) are a newly classiﬁed family
of immune cells of the lymphoid lineage. While they
could be found in both lymphoid organs and non-lym-
phoid tissues, ILCs are preferentially enriched in barrier
tissues such as the skin, intestine, and lung where they
could play important roles in maintenance of tissue
integrity and function and protection against assaults of
foreign agents. On the other hand, dysregulated activa-
tion of ILCs could contribute to tissue inﬂammatory
diseases. In spite of recent progress towards under-
standing roles of ILCs in the health and disease, mech-
anisms regulating speciﬁc establishment, activation,
and function of ILCs in barrier tissues are still poorly
understood. We herein review the up-to-date under-
standing of tissue-speciﬁc relevance of ILCs. Particu-
larly we will focus on resident ILCs of the skin, the
outmost barrier tissue critical in protection against var-
ious foreign hazardous agents and maintenance of
thermal and water balance. In addition, we will discuss
remaining outstanding questions yet to be addressed.
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INTRODUCTION
Innate lymphoid cells (ILCs) are the newly identiﬁed mem-
bers of the innate immune system. ILCs have the property of
classic lymphoid cells but lack rearranged antigen-speciﬁc
receptors (Spits et al., 2013; Walker et al., 2013). ILCs
encompass conventional natural killer (NK) cells and
lymphoid tissue inducer (LTi) cells, which were ﬁrst discov-
ered in 1975 and 1997, respectively (Kiessling et al., 1975a;
Kiessling et al., 1975b; Mebius et al., 1997), and other
recently described subsets. ILCs can be generally identiﬁed
by their expression of certain subunits of cytokine receptors
such as CD25 (interleukin (IL)-2 receptor α) and CD127 (IL-7
receptor α) but no cell-surface molecules that identify the
other types of immune cells (lineage marker-negative or
Lin−) (Artis and Spits, 2015). While ILCs could be found in
nearly every tissue and organ, they are preferentially enri-
ched in barrier tissues such as the skin, intestine and lung,
where they participate in local tissue homeostasis and
inﬂammation (Artis and Spits, 2015; McKenzie et al., 2014).
SUBSETS OF INNATE LYMPHOID CELLS
In analog to helper T (Th) cells, ILCs are conventionally
divided into three groups based on their differential expres-
sion of effector cytokines and developmental requirements
for transcription factors (Spits et al., 2013). The group 1 ILCs
are composed of ILCs capable of producing interferon γ
(IFNγ), which include NK cells and non-cytotoxic helper-like
ILC1s. NK cells are innate effector lymphocytes that are
capable of inducing granule-mediated cytotoxicity by
expressing perforin and granzymes, as well as producing
IFNγ and tumor necrosis factor α (TNFα) (Herberman et al.,
1975a; Herberman et al., 1975b; Kiessling et al., 1975a;
Kiessling et al., 1975b; Vivier et al., 2011). On the other hand,
non-cytotoxic ILC1s are innate helper lymphocytes that are
capable of producing IFNγ, TNFα and other Th1-associated
cytokines, but lack cytotoxic abilities (Artis and Spits, 2015;
Bernink et al., 2013; Vonarbourg et al., 2010). Recent studies
identiﬁed additional developmental and phenotypic differ-
ences between NK and ILC1s (Constantinides et al., 2014;











Klose et al., 2014). While eomesodermin (Eomes) is required
for development of NK cells, T-bet and GATA3 are critical for
ILC1s (Daussy et al., 2014; Gordon et al., 2012; Yagi et al.,
2014). In addition, NK cells re-circulate in the blood while
ILC1s predominantly reside in tissues (Sojka et al., 2014).
Group 2 ILCs produce Th2-associated cytokines such as
IL-4, IL-5, and IL-13 when activated, and depend on GATA3
and RORα for their development (Halim et al., 2012; Hoyler
et al., 2012). Group 3 ILCs are highly heterogeneous,
although they preferentially produce Th17-assciated cytoki-
nes including IL-17A and IL-22 and require RORγt for the
development. Based on their expression of the chemokine
receptor CCR6, group 3 ILCs can be divided into two subsets
(Klose et al., 2013; Sawa et al., 2011). CCR6+ ILC3s consist
of CD4+ and CD4− LTi cells, while CCR6− ILC3s are com-
posed of two subpopulations that have distinct expression of
the natural cytotoxicity receptor (NCR) NKp46 (Klose et al.,
2013; Rankin et al., 2013).
ILCs of the different groups can show certain functional
plasticity. For example, in response to IL-12 and IL-18,
CCR6−NKp46− ILC3s increase expression of T-bet and dif-
ferentiate into CCR6−NKp46+ ILC3s, which can further
increase T-bet and decrease RORγt expression and differ-
entiate into ex-RORγt+ ILC3s that display ILC1-like functions
with increased production of IFNγ and decreased IL-17A and
IL-22 (Artis and Spits, 2015; Bernink et al., 2013; Cella et al.,
2010; Klose et al., 2013; Vonarbourg et al., 2010). Using the
single cell transcription analysis, a recent study found that
there are signiﬁcant heterogeneities within ILCs and that
some of them display transcription proﬁles associated with
more than one group of ILCs, consistent with the notion that
they are of transition stages (Gury-BenAri et al., 2016).
DEVELOPMENT OF INNATE LYMPHOID CELLS
Common lymphoid progenitor cells of the bone marrow give
rise to all lymphocytes, including ILCs. Several intermediate
progenitors have been identiﬁed that have the potential to
give rise to different subsets of ILCs. Committed ILC pre-
cursors can differentiate into all ILC subsets, including NK
cells, but not T and B cells (Seillet et al., 2014; Yu et al.,
2014). They are termed α-lymphoid precursor (αLP) cells
because they express the integrin α4β7, but also known as
common innate lymphoid progenitor (CILP). αLP cells
express the chemokine receptor CXCR6 and require the
transcription factor NFIL3 for development (Seillet et al.,
2014; Yu et al., 2014). Downstream of αLP, two populations
of ILC precursor cells have been identiﬁed based on the
expression of inhibitor of DNA binding 2 (Id2) and promyeloid
leukemia zinc ﬁnger (PLZF) (Constantinides et al., 2014;
Klose et al., 2014). Common helper-like innate lymphoid
progenitor (CHILP) cells are Id2+Lin−IL-7Rα+α4β7+CD25−
and dependent on GATA3 for development. CHILP can give
rise to non-cytotoxic ILC1s, ILC2s and ILC3s, but no NK
cells (Klose et al., 2014). Innate lymphoid progenitor (ILCP)
cells are PLZFhighLin−IL-7Rα+cKit+α4β7highCXCR6−. ILCP
differentiates efﬁciently into the majority of ILC subsets
except NK cells and LTi cells (Constantinides et al., 2014).
ILCP is thus placed downstream of CHILP because ILCP
has a more restricted differentiation potential than CHILP.
More recently, a population of the transcription factor TCF-1+
early ILC progenitor (EILP) cells were also described (Yang
et al., 2015). The TCF-1+ EILP cells are IL-7Rαneg/low-
Thy1
−
Lin−CD122−CXCR6− and express low levels of PLZF.
EILP could develop into all subsets of ILCs, including con-
ventional NK cells, but not T/B cells (Yang et al., 2015).
TCF-1 knockout mice have reduced EILP as well as NKP
and CHILP, suggesting that TCF-1 is critical for development
of EILP and that NKP and CHILP are downstream of EILP
(Yang et al., 2015). The relationship between EILP and αLP
is not fully characterized even though EILP seems to func-
tionally overlap with αLP in their ability to differentiate into
ILCs but not T/B cells. Detailed developmental pathway and
regulation of the ILC differentiation have been extensively
reviewed (Ishizuka et al., 2016; Seraﬁni et al., 2015; Yang
and Bhandoola, 2016; Zook and Kee, 2016).
FUNCTION OF INNATE LYMPHOID CELLS IN
MAINTENANCE OF TISSUE HOMEOSTASIS AND
HOST PROTECTION
ILCs are enriched in barrier tissues where they play impor-
tant roles in maintenance of tissue homeostasis, regulation
of equilibrium between the host and microbiota, and immu-
nity against pathogens (Artis and Spits, 2015; McKenzie
et al., 2014; Walker et al., 2013). In addition, ILCs participate
in the development of lymphoid tissues, tissue remodeling,
and metabolic homeostasis (Artis and Spits, 2015; McKenzie
et al., 2014; Walker et al., 2013).
Functions of NK cells of the group 1 ILC family have
been well established, which include killing virus-infected
cells through cytolysis mediated by granzymes and per-
forin, and targeting tumor cells that have lost expression of
the class I major histocompatibility complex (MHCI) (Biron
et al., 1999; Vivier et al., 2012). The other non-cytotoxic
ILC1s can produce high amounts of IFNγ and TNFα, con-
tributing to the protection of hosts against bacteria and
intracellular parasites (Klose et al., 2014; Klose et al.,
2013). More recently, it was also reported that ILC1s play
an important role in the early protection against tumor
genesis (Dadi et al., 2016).
ILC2s are a critical innate source of type 2 cytokines,
such as IL-4, IL-5, IL-9 and IL-13, which can induce
eosinophilia, mastocytosis, activation of alternatively acti-
vated macrophages, goblet cell hyperplasia and muscle
contractility, and tissue repair (Pulendran and Artis, 2012).
ILC2s can be activated by cytokines such as IL-25, IL-33,
and thymic stromal lymphopoietin (TSLP) (Hams et al.,
2014; Kim et al., 2013; McHedlidze et al., 2013). During
parasitic helminth infection, ILC2s are identiﬁed as an
important source of IL-13 critical for the parasite expulsion
(Moro et al., 2016; Neill et al., 2010; Price et al., 2010). ILC2s
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also express amphiregulin and are involved in tissue
repairing after virus infection (Monticelli et al., 2011). In
addition, growing evidence demonstrates roles of ILC2s in
metabolic homeostasis (Hams et al., 2013; Molofsky et al.,
2013; Stanya et al., 2013). ILC2s in visceral adipose tissue
produce IL-5 and IL-13 and maintain responses of eosinophil
and alternatively activated macrophages, lack of which
results in increased adiposity and insulin resistance (Molof-
sky et al., 2013). ILCs can respond to changes in nutrients
such as Vitamin A, deﬁciency of which leads to reduced
ILC3s but increased ILC2s in intestines and is associated
with defective antibacterial immunity but enhanced anti-hel-
minth immunity (Spencer et al., 2014). Circadian clock also
regulates cytokine production of intestinal ILC2s through
vasoactive intestinal peptides (Nussbaum et al., 2013).
The role of LTi cells of the group 3 ILCs family in the
development of lymphoid organs of lymph nodes (LNs) and
Peyer’s patches has long been recognized (De Togni et al.,
1994; Eberl et al., 2004). Lymphotoxin α1β2 produced by LTi
cells binds to lymphotoxinβ receptor on stromal cells to induce
the production of chemokines and upregulation of adhesion
molecules, which recruit leukocytes to form lymphoid struc-
tures (van de Pavert et al., 2009). ILC3s have also been
implicated in tissue repair following inﬂammation or damage in
multiple tissues, including intestines, thymi, and lungs (Du-
dakov et al., 2012; Sawaet al., 2011; Taubeet al., 2011). ILC3s
are an important source of IL-22, which promotes epithelial
cells to express antimicrobial peptides to protect against
pathogens (Sonnenberg et al., 2011; Zheng et al., 2008). In
addition, ILC3s interact with stromal cells and other immune
cells to maintain balance between the host and microbiota by
limiting dissemination of commensal bacteria and inappro-
priate immune responses to them (Sonnenberg et al., 2012).
PARTICIPATION OF INNATE LYMPHOID CELLS IN
PATHOGENESIS OF DISEASES
Although ILCs normally play host-protective roles, dysregu-
lated activation of ILCs could lead to inﬂammatory diseases
(Artis and Spits, 2015; McKenzie et al., 2014; Walker et al.,
2013). IFNγ-producing ILCs, including ILC1s and ex-RORγt+
ILC3s, can induce inﬂammation in the intestines of both mice
and humans (Bernink et al., 2013; Buonocore et al., 2010;
Fuchs et al., 2013). In the adipose tissue, high fat diet could
activate ILC1s to produce IFNγ and promote inﬂammatory
macrophage polarization and development of insulin resis-
tance (O’Sullivan et al., 2016).
Chronic ILC2 activation was reported to contribute to a
large variety of tissue inﬂammatory disorders such as asthma
in the lung and atopic dermatitis in the skin, which are gen-
erally associated with over-production of the type 2 inﬂam-
matory cytokines such as IL-4, IL-5, and IL-13. ILC2s expand
and produce the type 2 cytokines in mice with allergic lung
inﬂammation (Chang et al., 2011; Halim et al., 2014), con-
sistent with the increase of ILC2s in peripheral blood of
patients with asthma (Bartemes et al., 2014; Moffatt et al.,
2010). Increased frequency of ILC2s was found in lesional
skin of mouse models and human patients with atopic der-
matitis (Imai et al., 2013; Kim et al., 2013; Salimi et al., 2013).
ILC3s could contribute to inﬂammatory diseases and
tumorigenesis in various tissues. IL-17- and IL-22-producing
ILC3s have been linked with the inﬂammatory skin disease
psoriasis, inﬂammatory bowl disease, obesity-associated
asthma, and multiple sclerosis (Buonocore et al., 2010; Kim
et al., 2014b; Pantelyushin et al., 2012; Perry et al., 2012;
Powell et al., 2012; Teunissen et al., 2014; Villanova et al.,
2014). IL-22 produced by ILC3s can contribute to develop-
ment of colon cancer in a mouse model, consistent with the
presence of IL-22-producing CD3− cells within human col-
orectal carcinoma tumors (Kirchberger et al., 2013).
INNATE LYMPHOID CELLS ARE PREDOMINANTLY
TISSUE-RESIDENT CELLS
Speciﬁc functions of ILCs in homeostasis and inﬂammation
are associated with their unique localization in peripheral
tissues. Recently, several groups reported that ILCs are
predominantly tissue-resident cells that do not circulate in
the body. In parabiotic studies, helper-like ILCs in both non-
lymphoid tissues and lymphoid organs such as the small
intestine, salivary gland, lung, mensenteric lymph node, and
adipose tissue of two joined adult mice with shared blood
circulation systems remain locally and do not move from one
mouse to another (Gasteiger et al., 2015; O’Sullivan et al.,
2016). However, conventional NK cells are mostly circulating
cells (Peng et al., 2013; Sojka et al., 2014). Furthermore,
systemic inﬂammation or infection did not mobilize tissue-
resident ILCs into the circulation either (Gasteiger et al.,
2015). These suggest that ILCs or their progenitor cells
might settle in speciﬁc peripheral tissues at early ontogenic
stages and are maintained and expanded locally. Consistent
with this notion, progenitor cells of ILCs have been identiﬁed
in lymph nodes of humans that could give rise to all innate
lymphoid cells in the in vitro development analysis (Scoville
et al., 2016). In addition, the bone marrow reconstitution in
human patients with severe combined immunodeﬁciency
(SCID) due to mutation of the gene encoding the common γ
chain cytokine receptor subunit IL-2Rγ or the tyrosine kinase
JAK3 did not restore presence of ILCs in various peripheral
tissues (Vely et al., 2016), supporting the notion that tissue-
resident ILCs are established at early ontogenic stages.
Mechanisms regulating speciﬁc localization and mainte-
nance of ILCs in various peripheral tissues are still poorly
understood.
MIGRATION AND ESTABLISHMENT OF INNATE
LYMPHOID CELLS IN THE SKIN
Skin is the outmost barrier tissue constantly exposed to
assaults of various foreign agents. Skin is enriched with ILCs
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and ILCs of all the three groups could be found in the skin
(Yang et al., 2016). Based on expression of the transcription
factor GATA3 and the cytokines such as IL-4 and IL-5, ILC2s
account for a major fraction of total skin ILCs in adult mice
(Roediger et al., 2013; Yang et al., 2016). Although few ILCs
of the skin in mice express the transcription factor RORγt, a
signiﬁcant fraction of skin ILCs are capable of producing
IL-17A, suggesting that they are ILC3s or ILC3-like cells
independent of RORγt (Yang et al., 2016). However, their
lineage relationship with other RORγt-expressing ILC3s is
not known. The group 1 ILCs, including NK cells, are present
in the skin of mice (Luci et al., 2009; Yang et al., 2016), and
they account for a smaller fraction of total skin ILCs than
ILC2s or ILC3s in adult mice (Yang et al., 2016). On the other
hand, in the skin of fetal and newborn mice, there are
abundant NK1.1+ ILC1-type cells although their origin and
lineage association are not known (Almeida et al., 2015). As
in mice, ILCs of all the three groups are found in the healthy
skin of humans (Dyring-Andersen et al., 2014; Ebert et al.,
2006; Salimi et al., 2013; Teunissen et al., 2014; Villanova
et al., 2014). Based on their expression of the prostaglandin
D2 receptor CRTH2, ILC2s account for 25%–40% of skin
ILCs in humans (Dyring-Andersen et al., 2014; Salimi et al.,
2013; Teunissen et al., 2014; Villanova et al., 2014). ILC3s,
including both NCR+ and NCR− subsets, account for about
50% of total skin ILCs in humans (Dyring-Andersen et al.,
2014; Teunissen et al., 2014; Villanova et al., 2014). The rest
are ILC1s and others uncharacterized.
Since ILCs share many common regulatory pathways
with helper T cells for their development and function, we
investigated whether skin-speciﬁc ILCs are programmed in
skin-draining lymph nodes to acquire their skin-homing
property for establishment of their skin residency, paralleling
the process by which the skin-homing property of conven-
tional αβ T cells is imprinted in skin-draining lymph nodes
(Yang et al., 2016). Among the most skin-speciﬁc homing
molecules expressed on skin-homing T cells and ILCs is the
chemokine receptor CCR10 (Sigmundsdottir and Butcher,
2008; Sigmundsdottir et al., 2007; Xiong et al., 2012; Yang
et al., 2016). A ligand for CCR10, CCL27, is highly and
speciﬁcally expressed by keratinocytes of the healthy skin in
both humans and mice (Homey et al., 2000; Morales et al.,
1999). The adhesion molecules E- and P-selectin ligands
and chemokine receptors CCR4, CCR6, and CCR8 are also
involved in the skin-homing process in the healthy skin
(Austrup et al., 1997; Campbell and Butcher, 2002; Campbell
et al., 1999; Picker et al., 1993; Reiss et al., 2001; Weninger
et al., 2000). In addition, different sets of homing molecules
are involved in migration of immune cells to the inﬂamed skin
under speciﬁc inﬂammatory conditions than those under
homeostatic conditions (Lonsdorf et al., 2009; Masopust and
Schenkel, 2013; Mora and von Andrian, 2006). For example,
high induction of the chemokines CCL1 and CCL18 is found
in the lesional skin of patients with atopic dermatitis (Gom-
bert et al., 2005; Pivarcsi et al., 2004). The chemokine
receptor CXCR3 is involved in migration of T cells to the
inﬂamed skin, where its ligands CXCL9, CXCL10, and
CXCL11 are produced (Flier et al., 2001). While CCL27
could be upregulated in the skin under inﬂammatory condi-
tions of allergic contact dermatitis, atopic dermatitis, and
psoriasis (Homey et al., 2002; Moed et al., 2004), it is pro-
foundly suppressed in severe psoriatic skin lesions (Gud-
jonsson et al., 2010; Quaranta et al., 2014; Riis et al.,
2011a). In the same patient, CCL27 expression is much
lower in psoriatic lesional skin than in peri-lesional skin
(Karakawa et al., 2014; Riis et al., 2011a), suggesting that its
expression is associated with severity of the disease.
Indeed, CCL27 is upregulated in the skin by the inﬂamma-
tory cytokines TNFα and IL-1β at the early phase of inﬂam-
mation (Riis et al., 2011b; Vestergaard et al., 2004) but is
suppressed by pathognomonic cytokines such as IL-17A
and IFNγ at the late, severe stage of skin inﬂammation
(Kanda et al., 2005; Karakawa et al., 2014). We recently
found that CCR10 is critical for migration of T cells into the
skin under steady-state conditions but is dispensable for
their inﬁltration into inﬂamed skin (Fu et al., 2016; Xia et al.,
2014). Like T cells, ILCs are also programmed in skin-
draining lymph nodes to acquire the CCR10 expression for
their migration to the skin under steady-state conditions
(Yang et al., 2016). In CCR10-knockout mice, ILCs gener-
ated in skin-draining lymph nodes is defective in migration
into the skin and increasingly diverted into spleens and other
sites where CCR10 ligands are not expressed (Yang et al.,
2016). Moreover, skin-speciﬁc CD207+ dendritic cells are
involved in the programming of skin-homing CCR10+ ILCs in
skin-draining lymph nodes (Yang et al., 2016) (Fig. 1).
Dependent on environmental cues of lymphoid organs in
which T cells and ILCs are activated, they could be also
imprinted to acquire homing properties to other distinct
peripheral tissues (Campbell and Butcher, 2002; Kantele
et al., 1999; Masopust and Schenkel, 2013; Mora et al.,
2003; Mora et al., 2005; Mora and von Andrian, 2006; Rott
et al., 1997; Weninger et al., 2000). A recent study reported
that ILCs undergo a homing receptor switch by upregulation
of CCR9 and α4β7 and downregulation of CCR7 in intestine-
draining mesenteric lymph nodes in a retinoic acid-depen-
dent manner for their migration into the intestine (Kim et al.,
2015). Together with the ﬁndings in the skin, these results
suggest that speciﬁc epithelial tissues and their associated
lymph nodes form an integral unit for generation and main-
tenance of tissue-speciﬁc ILCs. However, there might be
other regulatory mechanisms in establishment of tissue-
speciﬁc ILCs (Kim et al., 2015; Yang et al., 2016). In our
study of the generation of skin-speciﬁc CCR10+ ILCs in skin-
draining lymph nodes, local inﬂammatory conditions sup-
press programming of skin-homing CCR10+ ILCs (Yang
et al., 2016) (Fig. 1). Molecular factors regulating the dis-
tinctive generation and establishment of skin-speciﬁc ILCs
under homeostatic and inﬂammatory conditions are mostly
unknown.
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INTERACTION BETWEEN INNATE LYMPHOID
CELLS AND LOCAL IMMUNE AND NON-IMMUNE
CELLS IN PARTICIPATION OF SKIN INFLAMMATION
Compared to the healthy skin, ILC2s are increased in the
skin of patients with atopic dermatitis (Kim et al., 2013;
Salimi et al., 2013), suggesting that ILC2s are involved in
atopic dermatitis, an inﬂammatory disease associated with
over-active type 2 immune responses to environmental
allergens and barrier dysfunction (Leung, 2013). In a mouse
model of atopic dermatitis induced by topical application of
Calcipotriene (a synthetic Vitamin D3 derivative), ILC2-
derived IL-5 and IL-13 were reported to play an important
role in promoting the disease development (Kim et al., 2013)
(Fig. 1). It was also found that skin ILC2s are activated by
TSLP produced by skin keratinocytes in response to the
topical Calcipotriene-treatment (Kim et al., 2013). Another
study identiﬁed the role of IL-33 and IL-25 in activating skin
ILC2s to promote atopic dermatitis (Salimi et al., 2013).
Consistent with this, transgenic overexpression of IL-33 in
keratinocytes promotes accumulation of ILC2s in the skin
and induces atopic dermatitis-like disease (Imai et al., 2013).
Prostaglandin D2 (PGD2), acting through its receptor
CRTH2 expressed on human skin ILC2s, induces migration
and cytokine production of ILC2s in human atopic dermatitis
skin (Xue et al., 2014). Mast cells could be an important
source of prostaglandin D2 for activation of ILC2s (Barnig
et al., 2013; Roediger et al., 2013). IL-4 derived from baso-
phils was also shown to regulate the proliferation of skin
ILC2s, which express the IL-4 receptor IL-4Rα, and induce
atopic dermatitis-like disease (Kim et al., 2014a). Given the
role of E-cadherin in inhibiting the cytokine production of
ILC2s via binding to the inhibitory receptor KLRG1 expres-
sed on skin ILC2s, downregulation of E-cadherin in atopic
dermatitis skin might also contribute to the activation of skin
ILC2s (Salimi et al., 2013).
Increasing evidence implicates involvement of ILC3s in
psoriasis, a skin inﬂammatory disease largely resulting from
overproduction of Th17-associated cytokines such as IL-17A
(Dyring-Andersen et al., 2014; Pantelyushin et al., 2012;
Teunissen et al., 2014; Villanova et al., 2014). In a mouse
model of psoriasis induced by topical application of Imiqui-
mod, it was found that ILC3s are a cellular source of IL-17A
and IL-22 that mediate the Imiquimod-induced psoriasis-like
disease (Pantelyushin et al., 2012). In patients with psoria-
sis, NKp44+ ILC3s are increased in both lesional and non-
lesional skin and NKp44− ILC3s have the potential to dif-















































































Figure 1. Schematic illustration of establishment and function of ILCs in the skin homeostasis and inﬂammation. Under
homeostatic conditions, CCR10+ ILCs with regulatory properties are preferentially generated in skin-draining lymph nodes and
migrate into the skin where they promote the local immune homeostasis by controlling balanced presence and activation of other
immune cells. Under inﬂammatory conditions, there is reduced generation of CCR10+ regulatory ILCs in skin-draining lymph nodes.
In addition, there is also increased conversion of regulatory CCR10+ ILCs to inﬂammatory CCR10− ILCs, which promote immune
activation and inﬂammatory processes in diseases such as atopic dermatitis and psoriasis, depending cytokines produced by the
activated inﬂammatory ILCs.
Skin-resident innate lymphoid cells REVIEW









IL-1β and IL-23 (Teunissen et al., 2014; Villanova et al.,
2014). Increased percentages of NKG2D+ RORγt+CD56+
ILC3s were found in the psoriatic skin in a separate study
(Dyring-Andersen et al., 2014). There is a positive correlation
between reduction of ILC3s and therapeutic response in
psoriatic patients treated with anti-TNFα antibody (Villanova
et al., 2014), supporting involvement of ILC3s in psoriasis.
Cellular and molecular factors promoting activation of ILC3s
in participation of psoriasis are still not well understood but
could involve cytokines produced by myeloid, lymphoid,
epithelial, and stromal cells of the skin (Gasteiger and
Rudensky, 2014) (Fig. 1).
CROSSTALK BETWEEN INNATE LYMPHOID
CELLS AND OTHER SKIN IMMUNE CELLS IN
MAINTENANCE OF LOCAL TISSUE HOMEOSTASIS
AND HOST PROTECTION
While ILCs are relatively well studied for their participation in
development of skin inﬂammatory diseases, their physio-
logical role in maintenance of the skin homeostasis and host
protection is still poorly understood. Since ILC2s are capable
of producing amphiregulin, a member of epithelial growth
factor family, they could potentially contribute to wound
healing (Salimi et al., 2013). Similarly, IL-22 produced by
ILC3s is an important growth factor of keratinocytes. Indeed,
both ILC2s and ILC3s were recently reported to promote the
wound healing process in mouse models (Li et al., 2016; Rak
et al., 2016). The ILC2 response is promoted by the cuta-
neous injury in an IL-33-dependent manner (Rak et al.,
2016), while ILC3s are recruited into wounded dermis by
epidermal Notch1, which functions as a damage response
signal (Li et al., 2016).
Skin ILCs interact with other skin-resident immune cells to
maintain the immune homeostatic condition. In the steady-
state skin, the preferential interaction of ILC2s and mast cells
has been detected (Barnig et al., 2013; Roediger et al.,
2013). IL-13 produced by skin ILC2s suppresses the function
of mast cells in homeostatic conditions, suggesting a regu-
latory role of skin ILC2s (Roediger et al., 2013). ILCs might
also interact with T cells to regulate their homeostasis in the
skin (Yang et al., 2016), as reported in recent studies on the
cross-regulation between ILCs and T cells in several other
barrier tissues. ILC2s express MHCII and activate T cells to
induce production of IL-2, which in turn promote the prolif-
eration of ILC2s and their expression of type 2 cytokines for
worm expulsion in the gut (Oliphant et al., 2014). In a model
of allergic lung inﬂammation, IL-13 produced by ILC2s pro-
motes the migration of dendritic cells to draining lymph
nodes where they prime T cells to differentiate into Th2 cells
(Halim et al., 2014). The co-stimulatory molecule OX40L and
ILC2-derived IL-4 were reportedly involved in crosstalk
between ILC2s and T cells (Drake et al., 2014). Intestinal
MHCII-expressing ILC3s have the capacity to present anti-
gens to CD4+ T cells and dampen their responses to
microbiota (Hepworth et al., 2013). In addition, intestinal
microbiota induces the production of GM-CSF by ILC3s,
which promotes macrophages to produce retinoic acid and
results in a tolerogenic state through enhancing function of
regulatory T cells (Mortha et al., 2014). ILC3s could regulate
the gut ﬂora to control intestinal homeostasis and protect the
host from intestinal pathogen infection (Goto et al., 2014;
Guo et al., 2015; Qiu et al., 2013). Intestinal ILC3s also
promote the immunoglobulin A antibody production by B
cells through membrane lymphotoxin α1β2 (Kruglov et al.,
2013). In our study of skin ILCs, we found that interaction
between skin-speciﬁc CCR10+ ILCs and T cells plays a
critical role in maintaining the immune homeostasis of the
skin (Yang et al., 2016). In Rag1−/− mice that lack T and B
cells, there are signiﬁcantly reduced CCR10+ ILCs in the
skin, while transfer of CD4+ T cells could partially restore the
homeostatic presence of CCR10+ ILCs (Yang et al., 2016).
Reciprocally, ILCs regulate homeostasis of resident Tcells in
the skin. When transferred into Il2rg−/−Rag2−/− mice, which
lack all ILCs as well as T/B cells, donor CD4+ T cells in skin
of hosts contain signiﬁcantly higher percentages of IL-17A-
producing Th17 and IL-5-producing Th2 cells but much lower
percentages of IFNγ-producing Th1 cells than those trans-
ferred into Rag1−/− recipients that have ILCs (Yang et al.,
2016). In absence of ILCs, there are also signiﬁcantly
reduced presence of regulatory T cells in the skin, indicating
an important role of ILCs in regulating the homeostasis of
skin T cells (Yang et al., 2016) (Fig. 1).
PERSPECTIVES
The research over past several years has started to reveal
roles of ILCs in the skin and unravel mechanisms regulating
establishment and function of the skin-resident ILCs. How-
ever, several major questions remain to be addressed. First,
physiological functions of skin-resident ILCs in host protection
and immune homeostatic maintenance are still poorly
understood. While ILCs have been generally implicated in
protection against infection, control of commensal bacteria
and regulation of immune activation in various barrier tissues,
the function of resident ILCs speciﬁcally in the skin is not well
studied. Considering that ILCs are maintained locally in dif-
ferent barrier tissues, functions and regulation of ILCs in the
skin and other barrier tissues are likely regulated differently
with local environmental cues. For example, the CCR10/
CCL27 axis is involved in the regulation of resident ILCs in the
skin but not other sites (Yang et al., 2016). Further studies are
needed to understand how tissue-speciﬁc factors are involved
in regulation and function of skin-speciﬁc ILCs. Associated
with this, molecular mechanisms regulating tissue-speciﬁc
establishment of ILCs in the skin versus other barrier tissues
need further investigation. Furthermore, functions of different
groups of ILCs in the skin require delineation at different
ontogenic stages. For example, although group 1 ILCs,
including conventional NK cells, are abundantly present in the
skin of both humans andmice, particularly in the newborn and
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young (Batista et al., 2013; Ebert et al., 2006; Luci et al., 2009;
Teunissen et al., 2014; Villanova et al., 2014), their roles in
establishment of skin homeostasis are mostly unknown and
need further investigation.
Second, mechanisms regulating differential involvement
of ILCs in the skin homeostasis and inﬂammation are largely
unknown. Studies of ILCs of the skin and other barrier tis-
sues have showed that ILCs could be involved in both
homeostatic regulation and tissue inﬂammatory processes.
However, it is currently unknown whether and how ILCs
involved in homeostatic regulation are different from ILCs
involved in immune inﬂammatory processes in the skin. Our
studies have found that CCR10+ ILCs are dominant in the
healthy skin where they promote balanced maintenance of
resident T cells (Yang et al., 2016). In immune dysregulatory
or inﬂammatory conditions of Rag1−/−, Foxp3−/− or topical
Calcipotriol-treated wild-type mice, CCR10+ ILCs are
decreased while CCR10− ILCs are increased in the skin
(Yang et al., 2016), suggesting that CCR10+ and CCR10−
ILCs might be differently involved in skin immune homeo-
static regulation and activation (Fig. 1). Further study on how
CCR10+ and CCR10− skin ILCs are regulated and function
should help understand basic biology of the skin-speciﬁc
ILCs in the health and disease.
Third, the involvement of ILCs in promoting diseases has
raised interest in modulating ILC functions for the treatment
of diseases. In other tissues, antibodies against ILC2-acti-
vating cytokines, such as IL-25 and IL-33, as well as those
targeting ILC2-produced cytokines, including IL-5 and IL-13,
have been found to suppress ILC2 proliferation and function
in tissue inﬂammatory diseases in the lung (Gauvreau et al.,
2014; Hambly and Nair, 2014). Blockage of the binding of
prostaglandin D2 to CRTH2 expressed on human ILC2s
inhibits the migration and cytokine production of ILC2s
(Barnig et al., 2013; Xue et al., 2014). Montelukast, a leu-
kotriene receptor antagonist, inhibits the cytokine production
of ILC2s by blocking interaction between leukotriene D4 and
cysteinyl leukotriene receptor 1 (CysLT1R) expressed by
ILC2s (Doherty et al., 2013). ILC3s have been targeted in the
treatment of multiple sclerosis by anti-IL-2R antibody (Perry
et al., 2012). Antagonists of RORγt, which can regulate the
activity of Th17, might also target ILC3s (Bernink et al., 2015;
Solt et al., 2011; Withers et al., 2016). However, while there
is a report showing that inhibition of RORγt reduces differ-
entiation of CD127+ ILC1s to ILC3s (Bernink et al., 2015),
inhibition of RORγt does not impair function of mature ILC3s
(Bernink et al., 2015; Withers et al., 2016). How to target
ILCs in the skin to modulate their cytokine production for
treatment of skin inﬂammatory diseases is still understudied
and might represent a new area of study for disease
treatment.
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